B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes (PubMed:12920111, PubMed:3925015, PubMed:7684739). Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR (PubMed:12920111, PubMed:18474602, PubMed:7684739)
Forms homotetramers (PubMed:18474602, PubMed:7684739). Interacts with the heavy and light chains of cell surface IgM, the antigen-binding components of the BCR (PubMed:18474602)
Expressed on B-cells
A primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range, but can be low.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to MS4A10, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 8
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT00066469 | Lymphoproliferative Disorder | Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation | PHASE2 | COMPLETED |
| NCT00434629 | B-cell Lymphoma, Non-Hodgkin's Lymphoma | Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant | PHASE1 | COMPLETED |
| NCT00720135 | Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia | Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | PHASE1 | COMPLETED |
| NCT02151903 | B-cell Non-Hodgkin Lymphoma | Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL | PHASE1, PHASE2 | TERMINATED |
| NCT05668403 | Primary Membranous Nephropathy | A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy | PHASE1 | RECRUITING |
| NCT00517530 | Lymphoma | A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN) | PHASE1, PHASE2 | COMPLETED |
| NCT01874288 | B-cell Non-Hodgkin Lymphoma | A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL | PHASE1, PHASE2 | TERMINATED |
| NCT01920477 | Pemphigus Vulgaris | Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris | PHASE3 | TERMINATED |